ClinicalTrials.gg
CompletedNCT07007546Updated Jun 29, 2026

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

A Phase 1 interventional study of ABSK061 and ABSK061 in Healthy, sponsored by Abbisko Therapeutics Co, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To main objective is to evaluate the safety, tolerability, and pharmacokinetic profile of single or multiple oral doses of ABSK061 mini-tablets and to evaluate the effect of soft food with ABSK061 mini-tablets on its pharmacokinetic profile in healthy adult participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender:male or female participants, both male and female
  • Age: 18 to 45 years (including 18 and 45 years)
  • Weight: male participants weigh ≥ 50.0 kg, female participants weigh ≥ 45.0 kg, and is in the range of 19.0-26.0 kg/m2 (including cut-off value), and body mass index (BMI) = weight (kg)/height 2 (m2)
  • Able to understand and willing to comply with the study procedures, voluntarily participate in this clinical trial and sign the form before screening

Exclusion criteria

Exclusion Criteria:

  • Significant history of any hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, immunologic, musculoskeletal disease, or allergic disease (as determined by the Investigator)
  • Any ocular condition likely to increase the risk of eye toxicity
  • Gastrointestinal disorders that will affect oral administration or absorption of ABSK061
  • Females of and males who plan to father a child while enrolled in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Single oral dose of ABSK061

    Pharmacokinetic profile (PK) and safety of a single oral dose

    Drug: ABSK061

  • Experimental
    Multiple oral doses of ABSK061

    The safety, tolerability, and PK profile of multiple oral doses of ABSK061

    Drug: ABSK061

  • Experimental
    Food Effect on ABSK061

    Food Effect Tablet Formulation

    Drug: ABSK061

Interventions

  • A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.

  • A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.

  • Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics single-dose Cmax

    maximum plasma concentration (Cmax)

    Time frame: Up to 48 hours post-dose

  2. Pharmacokinetics multiple-dose Cmax

    maximum steady-state plasma concentration (Cmax)

    Time frame: Up to 24 hours post-dose

  3. Pharmacokinetics multiple-dose Cmin

    average steady-state trough plasma concentration (Cmin)

    Time frame: Up to 24 hours post-dose

  4. Pharmacokinetics single dose Tmax

    time to reach maximum plasma concentration (Tmax)

    Time frame: Up to 48 hours post-dose

  5. Pharmacokinetics single and multiple dose AUC

    area under the plasma concentration-time curve (AUC)

    Time frame: Up to 48 hours post-dose

  6. Pharmacokinetics multiple-dose RAUC

    accumulation ratio for AUC

    Time frame: Up to 24 hours post-dose

  7. Pharmacokinetics multiple-dose RCmax

    accumulation ratio for Cmax (RCmax)

    Time frame: Up to 24 hours post-dose

  8. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    number of participants with adverse events (AEs), serious adverse events (SAEs), as a measure of safety and tolerability

    Time frame: Initiation of study treatment up to 18-days post treatment

  9. Number of participants with abnormal laboratory tests results and abnormal physical exam findings

    Frequency in changes in laboratory parameters and physical signs of toxicity

    Time frame: Initiation of study treatment up to 18-days post treatment

Secondary outcomes

  1. Pharmacokinetics single dose CL/F

    apparent total clearance (CL/F)

    Time frame: Up to 48 hours post-dose

  2. Pharmacokinetics single dose Vz/F

    apparent volume of distribution (Vz/F)

    Time frame: Up to 48 hours post-dose

  3. Pharmacokinetics single dose t1/2

    half-life of ABSK061

    Time frame: Up to 48 hours post-dose

07

Study locations

1 site
  • Jiangnan University Affiliated Hospital
    Wuxi, Jiangsu 214062, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jul 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
Jun 6, 2025
StartActual
May 17, 2025
Primary completionActual
Jul 30, 2025
CompletionActual
Apr 14, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007546
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
May 17, 2025
Primary completion
Jul 30, 2025
Completion
Apr 14, 2026
Last update
Jun 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABSK061

Start the discussion